Antiretroviral Therapy
Antiretroviral emtricitabine (FTC) has low toxicity in HIV-infected patients
Published in Hepatitis Weekly, August 23rd, 2004
"Emtricitabine (FTC) is a synthetic nucleoside analogue of cytosine, which is intracellularly phosforylated to form the active form erntricitabine 5'-triphosphate (E5TP).
"E5TP inhibits both HIV and Hepatitis B reverse transcriptase. Clinical trials have shown FTC to be active as part of highly active anti-retroviral therapy in naive HIV-positive patients," researchers in England report.
"FTC may be dosed once daily and in vitro is less associated with the M184V mutation, which is classically associated with failure of treatment with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-08-23)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Consensus interferon and lactoferrin don't improve hepatitis C response rates - Diagnostics
Short-term hepatitis C virus infections reveal novel epitopes - Pediatric Cancer
HCV-associated liver disease in young cancer survivors shadows adult illness - Zoonotic Disease
Avian hepatitis E virus shares the features of swine and human HEV - Adverse Side Effects
Pegylated interferon causes dystonia in some patients infected with hepatitis B - Bacterial Infection
Methicillin-resistant S. aureus infections are epidemic in injection drug users - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
